These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 7237953

  • 1. [Salmon calcitonin in supportive therapy of neoplastic osteolysis. Preliminary report on a case of myeloma].
    Andriani A, Beni A, Beni RA, Calistri A, Gelli GF.
    Clin Ter; 1981 Jan 31; 96(2):183-91. PubMed ID: 7237953
    [No Abstract] [Full Text] [Related]

  • 2. Human calcitonin and malignant osteolysis.
    Nuti R, Righi G, Turchetti V, Vattimo A, Lazzaretto R, Martini G.
    Panminerva Med; 1986 Jan 31; 28(1):5-9. PubMed ID: 3960585
    [No Abstract] [Full Text] [Related]

  • 3. Multiple myeloma: optimal use of salmon calcitonin in the management of myeloma osteoclastic bone disease.
    Bataille R, Tenoudji-Cohen M, Rossi JF.
    Br J Haematol; 1983 Jan 31; 53(1):170-1. PubMed ID: 6848121
    [No Abstract] [Full Text] [Related]

  • 4. [Clinical use of calcitonin in the treatment of osseous localizations in breast carcinoma and multiple myeloma].
    Di Benedetto G, Corsini G, Puppo F, Zavarise GM.
    Clin Ter; 1981 Mar 31; 96(6):605-13. PubMed ID: 7285526
    [No Abstract] [Full Text] [Related]

  • 5. [Role of diphosphonates in the therapy of osteolysis and malignant hypercalcemia].
    Delmas PD, Charhon SA, Chapuy MC, Meunier PJ.
    Rev Rhum Mal Osteoartic; 1984 Dec 15; 51(11):663-6. PubMed ID: 6523018
    [No Abstract] [Full Text] [Related]

  • 6. [Synthetic salmon calcitonin in the therapeutic management of osteolytic metastases of breast carcinoma].
    Simone C, Racanelli A.
    Clin Ter; 1981 Aug 15; 98(3):247-67. PubMed ID: 7285537
    [No Abstract] [Full Text] [Related]

  • 7. [The extratumor mechanisms of osteolysis in multiple myeloma and the means for their correction].
    Golenkov AK, Lutskaia TD, Kliushnenkova EN, Tishenina RS, Valiulina LS, Novikov VE, Mitina TA.
    Ter Arkh; 1996 Aug 15; 68(7):58-61. PubMed ID: 8928074
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R, Croucher PI.
    Cancer Res; 2007 Jan 01; 67(1):202-8. PubMed ID: 17210700
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Agents affecting osteolysis in patients with breast cancer.
    Coombes RC, Neville AM, Gazet JC, Ford HT, Nash AG, Baker JW, Powles JT.
    Cancer Chemother Pharmacol; 1979 Jan 01; 3(1):41-4. PubMed ID: 161206
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. An electron microscopic investigation of human familial bone dysplasia. Inhibition of osteocytic osteolysis and induction of osteocytic formation of elastic fibers following calcitonin treatment.
    Nunez EA, Horwith M, Krook L, Whalen JP.
    Am J Pathol; 1979 Jan 01; 94(1):1-18. PubMed ID: 760539
    [Abstract] [Full Text] [Related]

  • 15. Intravenous neridronate for skeletal damage treatment in patients with multiple myeloma.
    Pittari G, Costi D, Raballo M, Maulucci L, Baroni MC, Mangoni M.
    Acta Biomed; 2006 Aug 01; 77(2):81-4. PubMed ID: 17172186
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M, Pogłód R, Pawlikowski J, Maj S, Nasiłowska B.
    Acta Pol Pharm; 2000 Nov 01; 57 Suppl():113-6. PubMed ID: 11293237
    [Abstract] [Full Text] [Related]

  • 18. Images in clinical medicine. Pathologic fracture and lytic lesions in multiple myeloma.
    Nair SR, Pearson SB.
    N Engl J Med; 2004 Oct 28; 351(18):1874. PubMed ID: 15509820
    [No Abstract] [Full Text] [Related]

  • 19. Chemotherapy did not enhance the anti-osteolytic effects of bisphosphonate in multiple myeloma bone disease.
    Ogata A, Kitano M, Hashimoto N, Iwasaki T, Hamano T, Kakishita E.
    J Bone Miner Metab; 2002 Oct 28; 20(4):240-2. PubMed ID: 12115071
    [No Abstract] [Full Text] [Related]

  • 20. [Bone lesions in patients with multiple myeloma].
    Umeda M, Takata M, Tsubuku M.
    Nihon Naika Gakkai Zasshi; 1995 Jul 10; 84(7):1070-4. PubMed ID: 7561360
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.